• Skip to primary navigation
  • Skip to main content
  • Skip to footer

BupPractice

Buprenorphine Training

  • Train a Team
  • About
  • Contact
  • Log In

Waiver Training for NPs & PAs Part 1: Buprenorphine Training

Home › Training › Waiver Training for NPs & PAs Part 1: Buprenorphine Training
As of April 15, 2019, the following activity does not meet the requirement for waiver training and will no longer be offered. The same content is available through our Buprenorphine Training Activity For Residents, but this activity will not qualify as waiver training and is not eligible for board-certified continuing education credit.

This activity is designed to change: Competence, Performance, Patient Outcome.  9hr(s)

Overview

Professional Practice Gaps

Educational Objectives:

After completing this activity participants will be able to:

  • Expand your practice to comply with the regulations and requirements of office-based buprenorphine treatment so that you can prescribe buprenorphine to your patients when appropriate
  • Relate buprenorphine’s pharmacological properties to its drug effects and understand the physiological effects of opioids and opioid treatments on patients
  • Identify, assess, and diagnose opioid use disorder in your patients
  • Use medical and substance use disorder history information to assess your patients in terms of suitability for treatment with buprenorphine
  • Provide effective and successful treatment to your patients throughout the phases of buprenorphine treatment: induction, maintenance, and discontinuation, and deal with complications that arise
  • Assess and adapt treatment guidelines to best treat your patients from specific patient populations, including those with psychiatric comorbidities, adolescents, the elderly, pregnant women, methadone transfers, and patients with pain
  • Prescribe, refer, or implement appropriate psychosocial therapies for treating opioid use disorder for your patients

Modules in this Training Activity

Activity Content

About Prescribing Buprenorphine
Impact of Opioid Use Disorder
Screening, Detection and Diagnosis of Opioid Use Disorder
Assessing Patients for Buprenorphine Treatment
Understanding Opioids Medications and Buprenorphine Formulations
Induction
Maintenance and Discontinuation
Pregnancy, Young Adults, Methadone Patients and Other Populations
Problematic Behaviors
Federal Laws and Regulations
Case: Chad Wright

Training Activity References

Audience and Accreditation

Audience: Providers

Type Est. Time Released Expires
DCBN 9 hr(s) 4/16/18 4/15/19
FAPA 9 hr(s) 4/16/18 4/15/19

DCBN Credit Statement: Clinical Tools, Inc. designates this enduring material for a maximum of 9 hour(s) of DCBN credit. Clinical Tools, Inc. is an approved provider by the District of Columbia Board of Nursing and is registered with CE Broker, Provider #50-1942.

FAPA Credit Statement: Clinical Tools, Inc. designates this enduring material for a maximum of 9 hour(s) of FAPA credit. Providers and other health professionals should claim only the credit commensurate with the extent of their participation in the activity.

A letter of completion for up to 9 hour(s) is available for non-physicians.

A score of 70% on the post-test is required to complete the activity.

Participation Requirements

Funding
Initial development of this activity was supported by a grant from the National Institute on Drug Abuse (#R44-DA12066).

Authors

As an ACCME accredited provider of continuing medical education, Clinical Tools, Inc.requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest to the provider. The ACCME defines ‘relevant’ financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Any conflicts of interest are resolved prior to the delivery of the educational activity to the learner. CTI does not permit individuals with financial conflicts of interest to participate in any stage of activity development.

T Bradley Tanner, MD (President, Clinical Tools, Inc.)
Disclosure: Has disclosed no relevant financial relationships. Dr. Tanner is the owner of Clinical Tools.
Read Bio
T. Bradley Tanner, MD is president of Clinical Tools and responsible for the vision of the company. He has received funding via grants and contracts from NIDA, NIAAA, NIMH, NCI, AHRQ, CDC, the Dept of Defense, and NASA to develop medical and health education projects. Dr. Tanner served as principal investigator on 2 NIDA grants to develop the DATA-2000 qualifying buprenorphine training program and clinical practice tools on Bup.ClinicalEncounters.com. He also has a strong background in technology and oversees the development and delivery of all Clinical Tools websites. Dr. Tanner is also a board-certified psychiatrist with experience in inpatient, outpatient, and emergency health settings. He currently treats patients and educates medical students and residents via his role as a Clinical Associate Professor of Psychiatry at the University of North Carolina at Chapel Hill.
Karen Rossie, DDS, PhD (Research Scientist, Clinical Tools, Inc. )
Disclosure: Has disclosed no relevant financial relationships.
Read Bio
Karen Rossie, DDS, PhD, directs projects at Clinical Tools. She majored in biology at Cleveland State University and studied dentistry at Case Western Reserve University followed by completing a Masters in pathology at Ohio State University, and later, a PhD in Psychology from the Institute of Transpersonal Psychology. She taught and practiced oral pathology and oral medicine for 15 years at the Ohio State University and the University of Pittsburgh, doing research in autoimmune disease, bone marrow transplantation, oral cancer, salivary gland disease, candidiasis, and diabetes. She has used this diverse background to lead or contribute to CTI projects related to tobacco cessation, opioid abuse treatment, anxiety, dementia care, alcohol use disorder, screening and brief interventions for substance abuse, obesity, and pain and addiction.

Reviewers

Judith Martin, MD (President of California Society of Addiction Medicine (CSAM) and Medical Director, BAART Turk Street Clinic)
Disclosure: Has disclosed no relevant financial relationships.
Read Bio
Dr. Martin’s residency specialty is family practice and she has worked in addiction medicine since 1986, and is certified in addiction medicine by the American Society of Addiction Medicine (ASAM). She works with heroin-addicted patients and their families in East Oakland, as the Medical Director of The 14th Street Clinic. She also serves as the Medical Director for the East Bay Community Recovery Project, a multi-service agency that includes a residential program for addicted women and their children, Project Pride. Dr. Martin has published several papers related to methadone maintenance and she has taught in the Division of Family Medicine at Stanford University School of Medicine. Currently, Dr. Martin is the President of the California Society of Addiction Medicine (CSAM), has served on CSAM’s executive council, and she chairs their Committee for the Treatment of Opiate Dependence. Since 2001, she has been involved in efforts to train physicians in opiate dependence and the use of buprenorphine for the treatment of opiate addiction. She is currently co-chair of the American Society of Addiction Medicine’s Buprenorphine Training Subcommittee.
Steve Applegate, MEd, MEd (President, Applegate Consulting, )
Disclosure: Has disclosed no relevant financial relationships.
Read Bio
Mr. Applegate has experience in substance use counseling, state initiatives impacting substance use, and professional training. His prior positions include director of higher education and instructional design at the North Carolina Governor’s Institute on Alcohol and Substance Abuse, project director of the North Carolina Initiative of the Mid-Atlantic Addiction Technology Transfer Center, and program director of the Addiction Sciences Center (an outpatient substance abuse treatment center at the University of Virginia Health Sciences Center). Mr. Applegate works as an on-site consultant and travels to the Clinical Tools (CTI) office on a monthly basis from his office in Richmond, VA. Mr. Applegate helped design the CTI Instructional Manual and works to continue to revise it as we expand our Instructional Design methodology. Mr. Applegate has extensive experience with online education and training, especially in the area of substance abuse. He often pushes the envelope of technology and brainstorms with Clinical Tools how we can utilize new technology in our products. He helped guide development of the curriculum plan and assessments in Phase I of the current project.

Most Recent Reviews

CTI Content Review: Thu, 11/21/2018
CTI Editorial Review: Mon, 11/29/2018

Next »
Funding Information Development of this website was funded by grant #R44DA12066, contract #HHSN271200655304C, contracts #HHSN271200900003C and Grant #1R44DA027245-01, from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health. The website contents are solely the responsibility of the authors and do not necessarily represent the official views of NIDA. Ongoing development and maintenance is funded by the training fee and Clinical Tools, Inc. No commercial support is received.
Clinical Tools is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

  • Contact Us
  • Copyright & Reproduction Guidelines
  • Privacy Policy
  • Terms of Service
  • Technology Requirements
  • 508 Compliance

Footer

developed & maintained by
ClinicalTools

A member of The Clinical Encounters Training Group: SBIRT Training | BupPractice | PainTx Challenge | CE:Vaping | CE:Alcohol | CE:Obesity | OpioidCME

Clinical Tools, Inc. staff have disclosed no relevant financial relationships.

Unless otherwise noted, individuals pictured are models and are used for illustrative purposes only.
This site is for educational purposes only and medical decisions should not be based solely on its content. This site, its authors, and its consultants do not assume liability for errors or omissions.
  • Facebook
  • LinkedIn
  • Twitter
feedback@clinicaltools.com

101 A Market St Chapel Hill, NC 27516
919-960-8118

Contact us

© 2023 · Clinical Tools, Inc · Log in

Professional Practice Gaps

Approximately 20 to 25% of primary care patients are likely to have a current substance use problem or health problem related to tobacco, alcohol, or drug use (Madras et al., 2009; Pilowsky & Wu, 2012). Screening, brief interventions, and referral to treatment (SBIRT) provided to all patients is effective in reducing alcohol, drug, and tobacco use (Agerwala & McCance-Katz, 2012; Pilowsky & Wu, 2012). Brief intervention in primary care is an effective and cost-efficient approach to reduce patients’ alcohol use (Seale et al., 2010; Madras et al., 2009). SBIRT was originally designed for patients with alcohol and tobacco use, but there is growing evidence that brief interventions for illicit drug use also leads to positive patient outcomes (Compton, 2009). Motivational interviewing is a set of structured counseling skills that has been shown to be one of the most effective means of motivating patients to change addictive behavior (Miller and Rollnick, 2012) and has been used successfully in primary care settings as the brief intervention phase of addiction treatment (Rahm et al., 2014).

Unfortunately, PCPs screen less than half of their patients for tobacco use and less than a third for alcohol use (Roche & Freeman, 2004; Seale et al., 2010). Brief interventions happen even less often than screening (NDCP, 2008). In patients who screened positive for substance use, less than 75% received a brief intervention. A lack of adequate training is the most frequently reported barrier to screening and brief intervention (Le et al., 2015). Appropriate follow-up is also happening less often as well (D’Amico et al., 2005). Only 48% of people with excessive alcohol use reported receiving follow-up, with most simply being told to “stop drinking”. There is also a practice gap in referral to treatment. Less than one-fifth of PCPs make a referral after screening positively for substance abuse or risky substance use (Madras et al., 2009). Primary care physicians need to understand the different types of specialty treatment so that they can make appropriate referrals for their substance abuse patients (SAMHSA, 1997).

Practice Gap References

Agerwala SM, McCance-Katz EF. Integrating screening, brief intervention, and referral to treatment (SBIRT) into clinical practice settings: A brief review. Journal of Psychoactive Drugs. 2012; 44: 307-317. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801194/ Accessed on: 2017-07-26.

Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA). TIP 24: A Guide to Substance Abuse Services for Primary Care Clinicians. Rockville, MD. Center for Substance Abuse Treatment. 1997. Available at: https://www.ncbi.nlm.nih.gov/books/NBK64827/ Accessed on: 2010-06-15.

Compton P. Urine toxicology screening: a case study. Emerging Solutions in Pain. 2009.

D’Amico EJ, Paddock SM, Burnam A, Kung FY. Identification of and guidance for problem drinking by general medical providers: results from a national survey. Medical Care. 2005; 43(3): 229-236. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15725979 Accessed on: 2013-10-24.

Le KB, Johnson AJ, Seale JP, Woodall H, Clark DC, Parish DC, Miller DP. Primary care residents lack comfort and experience with alcohol screening and brief intervention: A multi-site survey. Journal of General Internal Medicine. 2015; 30: 790-796. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25666210 Accessed on: 2015-06-19.

Madras BK, Compton WM, Avula D, et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites. Drug Alcohol Depend. 2009; 99: 280-295. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760304/ Accessed on: 2011-03-24.

Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. The Guilford Press. 2013. Available at: http://www.amazon.com/Motivational-Interviewing-Third-Edition-Applications/dp/1609182278 Accessed on: 2014-10-10.

Office of National Drug Control Policy. Screen & brief intervention. . 2008. Available at: https://www.ncjrs.gov/pdffiles1/ondcp/screen_brief_intv.pdf Accessed on: 2015-06-18.

Pilowsky DJ, Wu LT. Screening for alcohol and drug use disorders among adults in primary care: a review. Substance Abuse and Rehabilitation. 2012; 3: 25-34. Available at: https://www.dovepress.com/screening-for-alcohol-and-drug-use-disorders-among-adults-in-primary-c-peer-reviewed-article-SAR Accessed on: 2014-04-28.

Rahm AK, Boggs JM , Martin C, et al.. Facilitators and barriers to implementing SBIRT in primary care in integrated health care settings . Subst Abus. 2014. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25127073 Accessed on: 2015-05-27.

Roche AM, Freeman T. Brief interventions: good in theory but weak in practice. Drug and Alcohol Review. 2004; 23(1): 11-18. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14965883 Accessed on: 2013-10-24.

Seale JP, Shellenberger S, Velzsquez MM, Boltri JM, Okosun I, Guyinn M, Vinson D, Cornelius M, Johnson JA. Impact of vital signs screening and clinician prompting on alcohol and tobacco screening and intervention rates: a pre-post intervention comparison. BMC Fam Pract. 2010; 11:18: . Available at: https://www.ncbi.nlm.nih.gov/pubmed/20205740 Accessed on: 2014-07-28.

Login

Forgot Password?
Register New Account

Registration

  • Hidden
  • If you already have an account on one of our other Clinical Encounters sites, you do not need to create a new account, simply log in.
  • Hidden
  • Hidden
  • By registering, you agree to the Terms of Service and Privacy Policy. If you are a part of a group, you understand your participation information can be provided to the group organizer.
  • This field is for validation purposes and should be left unchanged.